Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.09 USD
Change Today +0.01 / 0.25%
Volume 2.0M
ARNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

arena pharmaceuticals inc (ARNA) Snapshot

Open
$4.14
Previous Close
$4.08
Day High
$4.17
Day Low
$4.01
52 Week High
01/8/15 - $6.28
52 Week Low
10/13/14 - $3.26
Market Cap
989.9M
Average Volume 10 Days
3.6M
EPS TTM
$-0.41
Shares Outstanding
242.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARENA PHARMACEUTICALS INC (ARNA)

arena pharmaceuticals inc (ARNA) Related Businessweek News

View More BusinessWeek News

arena pharmaceuticals inc (ARNA) Details

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, including potentially pulmonary arterial hypertension that is in Phase II clinical trials. The company’s products under development also comprise APD334, an modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which has completed Phase I single-ascending dose trials; APD371, an agonist of the cannabinoid receptor 2 that is in Phase I clinical trials intended for the treatment of pain and fibrotic diseases; and Temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I clinical trials. In addition it manufactures drug products under a toll manufacturing agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.

325 Employees
Last Reported Date: 03/2/15
Founded in 1997

arena pharmaceuticals inc (ARNA) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $746.8K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $441.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $415.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $394.0K
Compensation as of Fiscal Year 2014.

arena pharmaceuticals inc (ARNA) Key Developments

Arena Pharmaceuticals, Inc. Announces Management Changes

The board of directors of Arena Pharmaceuticals, Inc. appointed Jack Lief, the company’s president and chief executive officer, as its principal financial officer, and Jennifer K. Bielasz, the company's vice president, accounting and controller, as principal accounting officer. Both appointments will be effective on the last day of employment of its senior vice president, finance and chief financial officer, Robert E. Hoffman, which the company previously reported will be no later than July 10, 2015. Jack Lief, 69, is one of its co-founders and has served as a director and the company’s president and chief executive officer since April 1997. Mr. Lief also served as the chairman of the company’s board of directors from October 2007 to December 2014. In addition, Mr. Lief served as the company’s principal financial officer from March 2011 to August 2011.

Arena Pharmaceuticals, Inc. Announces Management Changes

Arena Pharmaceuticals, Inc. announced that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company. Mr. Hoffman is expected to remain in his current role at Arena until July 10, 2015. Following Mr. Hoffman's departure, Jennifer K. Bielasz, Arena's Vice President, Accounting and Controller, will continue to play a key leadership role in Arena's finance department. Ms. Bielasz joined Arena in 2001 and is responsible for managing all accounting activities. Prior to joining Arena, Ms. Bielasz served as the controller of both public and private companies and began her career at KPMG LLP.

Arena Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter of 2015

Arena Pharmaceuticals, Inc. reported earnings results for the first quarter of 2015. For 2015, the company recorded revenues of $12.3 million compared to $6.8 million for 2014. Net loss was $24.3 million for 2015 or $0.10 per share on a fully diluted basis compared to a net loss of $25.3 million for 2014 or $0.12 per share fully diluted.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARNA:US $4.09 USD +0.01

ARNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $7.78 USD -0.44
Array BioPharma Inc $5.76 USD -0.08
Orexigen Therapeutics Inc $3.91 USD -0.48
Progenics Pharmaceuticals Inc $8.43 USD -0.99
Rigel Pharmaceuticals Inc $2.85 USD -0.08
View Industry Companies
 

Industry Analysis

ARNA

Industry Average

Valuation ARNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.7x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit www.arenapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.